CD274 and neoplasm: Future studies in bigger cohorts are needed to investigate the role of these biomarkers and explore whether checkpoint inhibitors can be administered in a broader patient population, irrespective of PD-L1, MSI-H/dMMR, or tumor mutational burden status.